Welcome to our dedicated page for Skinhealth Systems news (Ticker: SKIN), a resource for investors and traders seeking the latest updates and insights on Skinhealth Systems stock.
SkinHealth Systems Inc. reports developments tied to its global medical aesthetics business, with recurring updates on financial results, margin performance, adjusted EBITDA, installed-base activity and its recurring consumables model. The company, formerly The Beauty Health Company, trades on the Nasdaq Capital Market under the symbol SKIN.
Company news also covers the Hydrafacial platform, SkinStylus microneedling and nano-channeling treatments, HydraScalp with Keravive, provider adoption, consumer skin-health research, board appointments and the completed corporate rebrand to SkinHealth Systems.
BeautyHealth (NASDAQ: SKIN), the company behind Hydrafacial, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close. The company will host an investor conference call at 4:30 p.m. Eastern Time following the results release.
Investors and interested parties can access:
- Live webcast of the call on BeautyHealth's investor relations website
- Supporting materials for the presentation
- Recording of the call (available approximately three hours after conclusion)
The company maintains transparency through various communication channels, including SEC filings, press releases, public conference calls, and their investor relations website, ensuring compliance with Regulation FD disclosure obligations.
BeautyHealth (NASDAQ: SKIN) reported Q4 2024 financial results, with net sales of $83.5 million, down 13.8% year-over-year, and full-year 2024 net sales of $334.3 million, declining 16.0% from 2023.
The company's active install base grew to 34,735 units from 31,446 in the prior year, driving growth in consumable sales. However, overall revenue decreased due to fewer unit placements, impacted by challenging macroeconomic conditions. Q4 gross margin improved to 62.7% from 47.2% in Q4 2023.
The company reported a Q4 net loss of $(10.3) million, relatively flat compared to $(9.4) million in Q4 2023. Adjusted EBITDA improved to $9.0 million from $3.4 million in Q4 2023, driven by lower operational spend and higher gross margins. Cash position stood at $370.1 million as of December 31, 2024.
BeautyHealth (NASDAQ: SKIN) has scheduled its fourth quarter and full year 2024 financial results announcement for March 12, 2025, after market close. The company, known for its flagship brand Hydrafacial, will host an investor conference call at 4:30 p.m. Eastern Time following the results release.
Interested parties can access the live webcast and supporting materials through BeautyHealth's investor relations website. A recording of the call will be made available approximately three hours after its conclusion.
BeautyHealth (NASDAQ: SKIN) has appointed Stephen J. Fanning to its Board of Directors, effective December 12, 2024. Fanning, a medical aesthetics veteran and former Hydrafacial Chairman (2016-2020), brings extensive industry experience to the role. His previous positions include President and CEO of Spectrum Solutions, leadership at Z-Medica, Solta Medical, and Johnson & Johnson. He currently serves as Chairman for Champion Manufacturing and LKC Technologies.
Fanning will join both the Nominating & Corporate Governance Committee and the Audit Committee, bringing the total board membership to eight directors. BeautyHealth Executive Chairman Brent Saunders highlighted Fanning's expertise in medical aesthetics and proven track record in driving global growth as valuable assets for the company's future growth and profitability initiatives.
BeautyHealth (NASDAQ: SKIN) has released its 2024 Skintuition Report, highlighting key trends in the beauty and skincare industry. The report reveals significant consumer shifts towards skinimalism and clinically proven treatments. Notable metrics include an 8% increase in Hydrafacial Perk Lip Treatments and a 55% surge in neck and décolleté treatments globally compared to the previous year.
The report identifies key trends for 2025, including the medicalization of beauty, rise of skintellectual consumers, skinimalism revival, focus on beautility, and tailored treatments. The company's Hydralock HA Booster, which triples hydration after one treatment, has become their most successful branded booster launch to date.
The Beauty Health Company (NASDAQ: SKIN) announced its Q3 2024 financial results, reporting net sales of $78.8 million, a decrease of 19.1% year-over-year. Gross margin improved to 51.6% from -12.9% in Q3 2023, driven by the absence of previous charges. Adjusted gross margin increased to 69.5%. Net loss narrowed to $18.3 million from $73.8 million in the prior year. Adjusted EBITDA was $8.1 million, down from $9.1 million in Q3 2023. The company sold 1,118 delivery systems, down from 2,140 units, reflecting a challenging macroeconomic environment. BeautyHealth revised its full-year net sales guidance to $322-$332 million and improved adjusted EBITDA guidance to -$2 to $4 million. Strategic moves included centralizing manufacturing in Long Beach and enhancing its commercial leadership.
The Beauty Health Company (NASDAQ: SKIN), known for its Hydrafacial™ brand, has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024, after market close. The company will host an investor conference call at 4:30 p.m. Eastern Time following the results release. Investors can access the live webcast and supporting materials through the company's investor relations website, with a recording available approximately three hours after the call concludes.
The Beauty Health Company (NASDAQ:SKIN), known for its flagship brand Hydrafacial™, has announced a video poster abstract presentation at the upcoming American Society for Dermatologic Surgery (ASDS) meeting in Orlando, Florida from October 17-20, 2024. The presentation will focus on the efficacy and safety of Hydrafacial treatments combined with non-ablative fractional laser and intense pulsed light (IPL) full-face treatments.
CEO Marla Beck highlighted the significance of this presentation, stating that it will provide scientific validation for the complementary effects of Hydrafacial with other aesthetic treatments. The study, titled 'A Randomized, Split-face, Prospective, Study to Assess the Efficacy and Safety of Hydradermabrasion after 1927nm Non-ablative Fractional Laser or Intense Pulsed Light Full-Face Treatments', will be presented by Dr. Michael Abrouk. The abstract emphasizes the synergistic effects of Hydrafacial when combined with non-ablative laser and IPL treatments, showcasing its ability to enhance overall skin quality, hydration, and treatment outcomes.